Segment Information (Tables)

3 Months Ended

Mar. 31, 2023

Reportable segment information was as follows:


	Three Months Ended
	March 31,
(DOLLARS IN MILLIONS)	2023		2022
Net sales:
Nourish	$	1,653	$	1,731
Health & Biosciences	513		661
Scent	608		585
Pharma Solutions	253		249
Consolidated	$	3,027	$	3,226
Segment Adjusted Operating EBITDA:
Nourish	$	208	$	329
Health & Biosciences	131		192
Scent	105		116
Pharma Solutions	59		65
Total	503		702
Depreciation & Amortization	(276)		(303)
Interest Expense	(111)		(72)
Other (Expense) Income, net	(6)		16
Restructuring and Other Charges (a)	(52)		(2)
Acquisition, Divestiture and Integration Related Costs (b)	(31)		(49)
Strategic Initiatives Costs (c)	(13)		—
Regulatory Costs (d)	(5)		—
Other (e)	5		(7)









Income Before Taxes	$	14	$	285

_______________________


(a)			For 2023 and 2022, represents costs primarily related to severance as part of the Company's restructuring efforts.
(b)			For 2023 and 2022, primarily represents costs related to the Company's actual and planned acquisitions, sales and planned sales of businesses and integration related activities primarily for Frutarom and N&B. These costs primarily consisted of external consulting fees, professional and legal fees and salaries of individuals who are fully dedicated to such efforts. For 2023, integration costs primarily relate to IT costs for the N&B integration. For the three months ended March 31, 2023, business divestiture and integration related costs were approximately $21 million and $10 million, respectively. For the three months ended March 31, 2022, business divestiture, integration related and acquisition related costs were $30 million, $18 million and $1 million, respectively.
(c)			Represents costs related to the Company's strategic assessment and business portfolio optimization efforts and reorganizing the Global Shared Services Centers, primarily consulting fees.
(d)			Represents costs primarily related to legal fees incurred for the ongoing investigations of the fragrance businesses.
(e)			For 2023, represents gains from sale of fixed assets. For 2022, represents shareholder activist related costs, primarily professional fees, and severance costs, including accelerated stock compensation expense, for certain executives who have been separated from the Company.

Net sales, which are attributed to individual regions based upon the destination of product delivery, were as follows:


	Three Months Ended March 31,
(DOLLARS IN MILLIONS)	2023		2022
Europe, Africa and Middle East	$	1,070	$	1,128
Greater Asia	688		744
North America	905		1,002
Latin America	364		352
Consolidated	$	3,027	$	3,226


	Three Months Ended March 31,
(DOLLARS IN MILLIONS)	2023		2022
Net sales related to the U.S.	$	871	$	901
Net sales attributed to all foreign countries	2,156		2,325